HOLISTA COLLTECH LIMITED — Investor Presentation 2021

Nov 11, 2021

Investor Presentation November 2021

==> picture [246 x 76] intentionally omitted <==

Company Overview (ASX: HCT) World-leading technologies & global reach

Holista Colltech is an emerging Australian developer of unique health and wellness products in the US$4.5 trillion Global Health and Wellness Industry (see Note 1)

• Successfully commercialised portfolio of patent-

protected/proprietary technologies

• Established track record with ~$7m in annual sales

Note 1 :https://globalwellnessinstitute.org/press-room/statisticsand-facts/

Key Market Stats*
Market Cap	$14.9m
52-week Trading Range	4.8¢ - 9.3¢
Average Daily Vol.	259,470
No. of Shares on Issue	275.4m
Top 20 Shareholders	68%

• Key products include low-GI food ingredients used by leading food manufacturers, all-natural sanitisers for consumer and industrial applications, market leading dietary supplements and disease-free ovine Collagen.

*As of 10/11/21

==> picture [132 x 41] intentionally omitted <==

2 Investor Presentation November 2021

Year of Achievements Foundations for a stronger FY22

Tests showing Signed Term Natshield™ Natshield™ sheet with trademark remains 1[st] order Berjaya effective on Exclusive approved in received for Country Farms Launch “List distribution China skin and hard SARS-CoV-2 surfaces for N” HVAC agreement for test kits solution to ovine up to 12 hours 1[st] order for control collagen into GI-Lite[TM] from airborne China Path-Away® Costanzo’s for COVID Signs deal with successfully US launch Costanzo’s to tested against launch world’s SARS-CoV-2 lowest GI clean Maiden sales label white of 80Less bread in US sugar substitute

==> picture [948 x 54] intentionally omitted <==

----- Start of picture text -----

2021
----- End of picture text -----

3 Investor Presentation November 2021

Business Divisions Growth engines

Healthy Food Ingredients				Infection Control Solutions

•Largest sales/profit contributor •Recovering strongly from COVID-19 impact •Market leading vitamin brand in Malaysia

==> picture [65 x 65] intentionally omitted <==

•1[st] to produce ovine collagen from Australian Sheep •Patented processes •Australian collagen highly sort after due to disease-free status •Product sold to cosmetics manufacturers

==> picture [132 x 41] intentionally omitted <==

4 Investor Presentation November 2021

Food Ingredients Developments & update

==> picture [185 x 131] intentionally omitted <==

Muffins, white breads and pasta made with GI Lite[TM] scored a GI reading of 48, 46 and 38 respectively

==> picture [479 x 58] intentionally omitted <==

----- Start of picture text -----

Sales increased by 45% Q3 2021 v Q3 2020, driven by GI Lite™
and 80Less™
----- End of picture text -----

==> picture [478 x 58] intentionally omitted <==

----- Start of picture text -----

Growth driven by Costanzo’s orders despite pandemic in USA
----- End of picture text -----

==> picture [478 x 59] intentionally omitted <==

----- Start of picture text -----

Stronger growth expected with Costanzo’s official launch in
December 2021
----- End of picture text -----

==> picture [478 x 69] intentionally omitted <==

----- Start of picture text -----

Partnership with Berjaya’s Country Farms opens opportunities
into several leading franchises in Malaysia (e.g. Starbucks,
Kenny Rogers and 7-Eleven)
----- End of picture text -----

==> picture [203 x 68] intentionally omitted <==

==> picture [185 x 71] intentionally omitted <==

==> picture [132 x 41] intentionally omitted <==

5

Investor Presentation November 2021

Infection Control Developments & update

==> picture [207 x 144] intentionally omitted <==

==> picture [295 x 240] intentionally omitted <==

----- Start of picture text -----

6
Investor Presentation November 2021
----- End of picture text -----

==> picture [478 x 60] intentionally omitted <==

----- Start of picture text -----

Natshield™received Trademark approval for sales in
China
----- End of picture text -----

==> picture [478 x 61] intentionally omitted <==

----- Start of picture text -----

Persistence tests proof Natshield™lasts up to 12 hours
on skin and hard surface
----- End of picture text -----

==> picture [478 x 60] intentionally omitted <==

----- Start of picture text -----

Launching world’s first Nasal Protecting Balm active for
12 hours in Q4 2021 in Malaysia, US and South America
----- End of picture text -----

==> picture [478 x 61] intentionally omitted <==

----- Start of picture text -----

Securing test kit opportunities in the US, South America
and UK (pending regulatory approvals)
----- End of picture text -----

==> picture [216 x 72] intentionally omitted <==

==> picture [132 x 41] intentionally omitted <==

Infection Control Natshield™Nasal Protecting Balm

==> picture [229 x 87] intentionally omitted <==

==> picture [88 x 259] intentionally omitted <==

==> picture [205 x 245] intentionally omitted <==

==> picture [478 x 77] intentionally omitted <==

----- Start of picture text -----

Persistence tests prove Natshield™lasts up to 12 hours
on skin and hard surface by SGS and Chemlab in
Malaysia
----- End of picture text -----

==> picture [478 x 61] intentionally omitted <==

----- Start of picture text -----

Nasal protecting balm formulated to be PH 5.5 which
prevents pathogen growth on skins
----- End of picture text -----*

==> picture [479 x 60] intentionally omitted <==

----- Start of picture text -----

Contains 5% Path-Away® / Protectene™that has been
proven to kill SARS-CoV-2 99.9% within 2 minutes
----- End of picture text -----

==> picture [478 x 77] intentionally omitted <==

----- Start of picture text -----

Launch in North America by Igalen in Q4
Pending registration in Latin American countries staring
with Columbia
----- End of picture text -----

• Source : https://www.usgs.gov/media/images/ph-describes-acidity-aqueous-liquid

==> picture [216 x 64] intentionally omitted <==

==> picture [132 x 41] intentionally omitted <==

7

Investor Presentation November 2021

Dietary Supplements Developments & update

==> picture [226 x 34] intentionally omitted <==

==> picture [274 x 190] intentionally omitted <==

==> picture [163 x 59] intentionally omitted <==

==> picture [109 x 101] intentionally omitted <==

==> picture [71 x 33] intentionally omitted <==

==> picture [77 x 23] intentionally omitted <==

==> picture [478 x 58] intentionally omitted <==

----- Start of picture text -----

Double digit growth in Sales Q3 2021 v Q3 2020
----- End of picture text -----

==> picture [478 x 61] intentionally omitted <==

----- Start of picture text -----

Growth driven by rebound from COVID and launch of
new supplement (Hydro D – water soluble Vitamin D)
----- End of picture text -----

==> picture [478 x 60] intentionally omitted <==

----- Start of picture text -----

“Cash Cow” business that contributed ~70% of 2021
Group revenue with market leading products
----- End of picture text -----

==> picture [478 x 61] intentionally omitted <==

----- Start of picture text -----

Global Supplement market growing at 8.6% CAGR
from 2021-2028
----- End of picture text -----

• Source: https://www.grandviewresearch.com/industry-analysis/dietary-supplements-market

==> picture [132 x 41] intentionally omitted <==

8 Investor Presentation November 2021

Ovine Collagen Developments & update

Guangzhou Sinbio Cosmetic Co Ltd is a Chinese stateowned enterprise that exclusively represents leading cosmetic brands like Ceeture, Estee Lauder and SK-II China. Guangzhou Sinbio sells cosmetics via a network of 45,000 directowned stores.

==> picture [89 x 63] intentionally omitted <==

==> picture [55 x 55] intentionally omitted <==

==> picture [478 x 64] intentionally omitted <==

----- Start of picture text -----

World’s 1 [st] and only company to extract ovine collagen
from Australian sheep
----- End of picture text -----

==> picture [477 x 77] intentionally omitted <==

----- Start of picture text -----

Production facility in Collie, Western Australia using
patented technology to produce premium grade ovine
collagen
----- End of picture text -----

==> picture [593 x 50] intentionally omitted <==

----- Start of picture text -----

productions upon successful conclusion of trials
----- End of picture text -----

==> picture [478 x 66] intentionally omitted <==

----- Start of picture text -----

Binding sales agreement to see Holista expand plant
capacity over the next four years
----- End of picture text -----

==> picture [247 x 64] intentionally omitted <==

==> picture [132 x 41] intentionally omitted <==

9 Investor Presentation November 2021

Unlocking Value for Ovine Collagen Significant growth options

Grow

Establish world leading collagen offering through Guangzhou Sinbio opportunity and existing customer relationships

==> picture [247 x 64] intentionally omitted <==

==> picture [521 x 126] intentionally omitted <==

----- Start of picture text -----

Partner Upgrade
To consider developing food-grade Produce medical-grade collagen to
collagen in future capitalise on large new markets
----- End of picture text -----

==> picture [132 x 41] intentionally omitted <==

Investor Presentation November 2021

10

Outlook Roadmap to growth

Positive Outlook

Improved 2022 results expected

Healthy Food

• ✓ Multiple Growth Levers: Several significant growth opportunities that can lead to a significant step-change

• in earnings over short- to medium-term

• ✓ Improved Outlook : Trading conditions in 2021 show marked improvement over previous year

• ✓ Expanding Margins: Profit margins expected to improve on 2021 due to cost optimisation and organic growth

• ✓ Positive Tailwinds: Global trends of further over

• supportive growth medium- to longer-term for all divisions

• Improved demand for GI-Lite[TM] and 80Less[TM]

• •Growing consumer focus on healthier foods to drive growth

• •Trials with Berjaya’s Country Farms ongoing

• •Costanzo’s launching big promotional campaign in US for GI Lite[TM] bread

Infection Control

• Sales of Natshield™sanitisers expected to continue to grow

• •New product launches and potential expansion into China to fuel next phase of growth

• •Successful persistence testing will bolster demand for Natshield[TM]

Dietary Supplements

• Sales up double-digit & further growth expected in 2022

• •New products contributing to growth

• •Will remain a significant cash generator for Holista

Ovine Collagen

• Potentially a transformative deal with China

• •Major plant expansion when agreement becomes binding

• •Capex fully funded from customer deposits, grants and internal resources

==> picture [132 x 41] intentionally omitted <==

12 Investor Presentation November 2021

Investment Proposition Well-positioned for growth

==> picture [51 x 110] intentionally omitted <==

==> picture [51 x 50] intentionally omitted <==

----- Start of picture text -----

$
----- End of picture text -----

==> picture [52 x 114] intentionally omitted <==

Multiple growth avenues with defensive revenue streams Global reach with proven products sold around the world Large addressable and growing markets in health/wellness Positive outlook with further growth momentum expected Improved results expected and ready for 2022 prospects

==> picture [132 x 41] intentionally omitted <==

13 Investor Presentation November 2021

Board of Directors & Advisors Expertise to lead the group forward

==> picture [67 x 68] intentionally omitted <==

Rajen Manicka Executive Chairman MD & CEO

Dr Rajen spent nine years working for Big Pharma including Roche and CIBA Pharmaceuticals in various capacities including product and marketing manager. He is a prominent figure in the Malaysian biotech industry and is a member of the Malaysian Ministry of Health Standing Committee for Traditional Medicine.

==> picture [74 x 76] intentionally omitted <==

Walter Joseph Non-Executive Director

Successful track record working in senior management and consulting positions over the past five decades at several leading organizations, including the National Australia Bank, WesfarmersBunnings, P&O Ports, Water Corporation of Western Australia (WA) and the WA Department of Commerce and Trade.

==> picture [75 x 70] intentionally omitted <==

Loren King Non-Executive Director

Mrs Loren King has worked in corporate finance and senior administration roles with ASX listed companies, stockbroking and corporate advisory services for the past 15 years. Mrs King has a Bachelor of Psychology, is a Fellow Member of the Governance Institute of Australia holding a Graduate Diploma of Applied Corporate Governance and has a Certificate IV in Financial Services (Bookkeeping).

==> picture [74 x 75] intentionally omitted <==

Jay Stephenson Company Secretary

Mr Stephenson has been involved in business development for over 30 years including the past 25 years as Director, Chief Financial Officer and Company Secretary for various listed and unlisted entities He has been involved in business acquisitions, mergers, initial public offerings, capital raisings, business restructuring as well managing all areas of finance for companies.

==> picture [68 x 67] intentionally omitted <==

Arthur Martin Advisor

Founder and President of GICC. Dr Martin invented PathAway® and has conducted over 4,000 assessments for chem biological, bacterial and viral contamination. He pioneered the concept of “Prophylactic Air Management for Pathogen Control” and has an extensive list of publications and peer reviewed awards.

==> picture [68 x 68] intentionally omitted <==

Roscoe Moore Advisor

Dr Moore served as Assistant US Surgeon General, Rear Admiral of U.S. Public Health Service, Chief Epidemiologist with the Center for Device and Radiological Health at the U.S. FDA and Senior Epidemiologist within the National Institute for Occupational Safety and Health, Center for Disease Control (CDC).

==> picture [132 x 41] intentionally omitted <==

14 Investor Presentation November 2021

Disclaimer

This document has been prepared by Holista Colltech Limited and comprises written material/slides for a presentation concerning Holista Colltech Limited and its subsidiaries.

The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase, or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

Certain statements in this presentation are forward looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward looking statements speak only as at the date of this presentation. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Holista Colltech Limited that the forward looking statements contained in this presentation are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, Holista Colltech Limited and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss of damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom. Subject to any continuing obligation under applicable law or any relevant listing rules of the ASX, Holista Colltech Limited disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change of events, conditions, or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Holista Colltech Limited since the date of this presentation.

==> picture [132 x 41] intentionally omitted <==

15

To join our mailing list please email: update@holistaco.com

Thank You

For further information, please contact: Corporate Matters: investor@holistaco.com General Enquiries: enquiries@holistaco.com Investor/Media Relations: Brendon Lau (m: 0409 341 613, e: brendon@vantagepointpartners.com.au)

==> picture [124 x 117] intentionally omitted <==